Difference between revisions of "Part:BBa K4361021"

Revision as of 08:38, 12 October 2022 (view source) Larsvdb (Talk | contribs) ← Older edit		Revision as of 08:40, 12 October 2022 (view source) Larsvdb (Talk | contribs) Newer edit →
Line 26:		Line 26:
	<figcaption> <b>Figure 1.</b> 25 sequences similar to the BlcR operator from <i>A. tumefaciens</i> C58 (AE007872.2) were found with an nBLAST on NCBI (searching ‘somewhat similar sequences’ and word size of 7). Left: an unrooted tree of the sequences with the NCBI accession codes at the tips. Right: the multiple alignment of the sequences coloured by the percentage of identity with a normalized logo plot underneath and the consensus sequence. The new observed inverted repeats (IR1, IR2, IR3) are outlined. The sequences were aligned using MAFT and visualized with JalView. The tree was generated using TreeHugger 0.5 and visualized using FigTree v1.4.4.</figcaption>		<figcaption> <b>Figure 1.</b> 25 sequences similar to the BlcR operator from <i>A. tumefaciens</i> C58 (AE007872.2) were found with an nBLAST on NCBI (searching ‘somewhat similar sequences’ and word size of 7). Left: an unrooted tree of the sequences with the NCBI accession codes at the tips. Right: the multiple alignment of the sequences coloured by the percentage of identity with a normalized logo plot underneath and the consensus sequence. The new observed inverted repeats (IR1, IR2, IR3) are outlined. The sequences were aligned using MAFT and visualized with JalView. The tree was generated using TreeHugger 0.5 and visualized using FigTree v1.4.4.</figcaption>
	</figure>		</figure>
−

---

Revision as of 08:40, 12 October 2022

BlcR-binding oligo, 57 bp, consensus sequence

BlcR is a transcription factor originating from the bacterium Agrobacterium tumefaciens (Part:BBa_K4361100). In a homodimer state it contains a single DNA-binding domain that specifically binds one of two DNA sequences. Both sequences are so-called inverted repeat pairs (IRs), short DNA sequences whose ends are reverse complements of each other. For the Blc operator, these sequences are 'ACTCTAATgATTCAAGT' (IR1) and 'ATTAGttgaactCTAAT' (IR2), as further explained in Part:BBa_K4361001.
As their contribution to our partnership, the DTU iGEM 2022 team analyzed the BlcR binding operator with NCBI Blast. In total, they found 25 variants of the sequence originating from different strains of A. tumefaciens, varying in similarity to what we define as the wildtype oligo, Part:BBa_K4361001. Surprisingly, while they found that all sequences did have conserved nucleotides, these were not specifically for IR1 and IR2 but instead for alternative inverted repeats (see Sequence and Features and Usage and Biology below). From the multiple sequence alignment, two sequences were chosen to be further investigated by us: the consensus sequence formed by the most common nucleotide for each position in the alignment (this part), and the operator of A. tumefaciens strain Q15, because of its relatively low similarity with the wildtype sequence (Part:BBa_K4361022).

Sequence and Features

Usage and biology

In vivo the Blc operator consists of pair 1 and 2 linked together by a 3 nt spacer, and each pair can bind a single BlcR dimer (see Part:BBa_K4361100). With a spacer of specifically 3 nt, the centers of each pair are exactly 20 nt apart, which supports the hypothesis that the two dimers orient themselves at the same rotation angle to the DNA to form a tetramer. If the spacer were of a different length, the dimers would have different orientations to each other, possibly inhibiting tetramerization (see Part:BBa_K4361014). With two BlcR dimers bound and forming a tetramer, RNA polymerases originating from an upstream promoter are sterically hindered from moving along the DNA past the Blc operator, inhibiting expression of downstream blc genes, creating a selfregulating system. Each BlcR monomer contains a binding site that recognizes gamma-hydroxybutyrate (GHB) and derivative molecules. When a BlcR tetramer binds GHB with one of its binding sites, it reverts back to two dimers and unbinds from the DNA, once more enabling downstream transcription.

In our project, we make use of BlcR's abilities to bind a specific DNA sequence and to react to the presence of GHB by incorporating it into a capacitive biosensor. This biosensor contains two parallel metal plates that act as a capacitor, with a solution containing BlcR in between. One of the plates is covered in the wildtype BlcR-binding oligo. The sensor also contains BlcR dimers, which bind to the DNA oligos. When the dimer displace water molecules by binding to the DNA, the permittivity and thereby the capacitance of the capacitor changes, which can be measured and set as a baseline after an equilibrium has been reached. When the sensor then comes into contact with GHB or a derivative molecule (succinic semialdehyde (SSA) for the majority of our experiments) BlcR unbinds, which once again leads to a capacitance change. By continuously measuring the capacitance, the solution contacting the biosensor can be monitored for changes in its GHB content.

Oligo variants
The wildtype Blc operator has been theorized to not bind BlcR optimally, since BlcR regulates its own expression and that of proteins involved in the breakdown of GHB-like molecules. This means BlcR has to quickly unbind if said molecules are detected by A. tumefaciens, such that the bacterium can digest the molecules for nutrients. In our system, however, we would like BlcR to be more stably bound to DNA, such that it will only unbind in the presence of high GHB concentrations. This can be accomplished through two approaches: adjusting BlcR itself (see Part:BBa_K4361200 through Part:BBa_K4361227 and Part:BBa_K4361300 through Part:BBa_K4361319), or changing the DNA molecule it binds to. This set of Parts, Part:BBa_K4361000 up to Part:BBa_K4361022, shows our work on the second approach.

Alternative inverted repeats
As shown above in Sequence and Features as IR1, IR2 and IR3, with > and < respectively indicating forward and reverse direction, this consensus sequence seems to contain three sets of matching IRs that are each reverse complements of each other. Especially IR2 and IR3 are highly conserved in all sequences analyzed by DTU whereas the IRs mentioned in previous oligos are not. This suggests not only that these alternative repeat pairs are highly important for the function of the Blc operator, but possibly that the 'original' IRs are not the actual true binding site of BlcR. Furthermore, the results below show that BlcR may be able to bind this sequence more strongly than the wildtype DNA. While it is not yet known how BlcR interacts with these new binding sequences, according to our results the binding of BlcR to DNA may not be as well understood as previously thought and should be investigated further in future research. For example, a crystallography model of BlcR bound to DNA would make a significant contribution to research on this protein and similar transcription factors.
Figure 1 shows the result of the NCBI Blast, with the consensus sequence shown at the bottom of the multiple sequence alignment on the right. The alternative IRs are clearly visible as the nucleotides most highly conserved throughout the sequences. As AE007872.2 corresponds to Part:BBa_K4361001, it can be seen that the sequence of the wildtype oligo is fully conserved within the sequence of this part. According to literature, binding of BlcR to DNA should be wholly dependent on the presence of the known, 'original' IRs. This does not explain why the addition of nucleotides at the 5' end, which is effectively the only difference between the wildtype and consensus sequences, results in increased binding of BlcR to the DNA. However, these added nucleotides coincide with the forward-facing alternative IR1, which supports the hypothesis that BlcR has a different mechanism of binding to DNA than previously described in literature.

Results

As described in the Results section of Part:BBa_K4361000 and Part:BBa_K4361001, an electrophoresis experiment was performed with the majority of our designed oligos, wherein the aforementioned parts act respectively as the negative and positive control. By incubating them with BlcR and running them on a gel, the binding strength of BlcR to each sequence can be estimated by looking at the bands of free DNA and DNA bound by the protein. As can be seen in Figure 2, the amount of DNA bound by BlcR is increased significantly when compared to the results for the wildtype oligo. This suggests a higher binding affinity between BlcR and DNA, so this oligo was selected to be further analyzed, as described below.

In a second electrophoresis experiment, two runs were done for the two controls and five selected oligos that showed binding similar to or increased from the wildtype (Part:BBa_K4361007, Part:BBa_K4361008, Part:BBa_K4361009, this part, and Part:BBa_K4361022). One run was performed under similar conditions as those in the experiment described above, while SSA was added to the second run. As a substitute for GHB, it is expected that the addition results in the separation of BlcR tetramers into dimers, leading to them unbinding from the DNA. Indeed, Figure 3 shows that this is the case for all samples. More strikingly for the selected oligos, the amount of bound DNA drops from increased levels when compared to the wildtype oligo to similar levels after addition of SSA. This means that there is a relatively larger change in the amount of bound DNA, which would be beneficial for application in an electronic biosensor as the bigger change in the signal would be easier to measure.

For further details on the experiments with our DNA oligos and the results, see the Results page on our wiki.